我国基本药物可负担性实证研究

摘要

目的:为完善我国基本药物政策,提高基本药物可负担性提供参考.方法:收集2011年我国17省(区、市)的基本药物中标数据,选用治疗5种常见病的18种基本药物,参考世界卫生组织(WHO)和国际健康行动机构(HAI)对药品可负担性研究的标准方法,实证分析我国基本药物的可负担性情况.结果与结论:我国基本药物可负担性总体状况较好,但不同药品间可负担性差异较大,地区间差距不大,且原研药和仿制药的可负担性也存在一定差距.应大力推广和普及应用《基本药物临床应用指南》和《基本药物处方集》,完善基本药物招标制度,进一步调整原研药价格.%OBJECTIVE: To provide reference for the improvement of essential drug policies and affordability of essential drugs in China. METHODS: According to the essential drugs bid data in 17 provinces and cities in China in 2011, 18 kinds of essential drugs for 5 common diseases were selected, and the affordability of essential drugs was analyzed according to the standard drug price methodology of WHO and Health Action International (HAI). RESULTS & CONCLUSIONS: The affordability of essential drugs is better overall, but the affordability of different drugs are greatly different from one another. There is still a certain gap between original drug and generic drugs but the regional gap. It is recommended to promote the application of Guidance for Clinical Application of Essential Drugs and Essential Drug Formulary, improve the drug bidding system and further adjust the price of original drug.